Cerebral infarction
Conditions
Interventions
experimental group:pentoxifylline sustained-release tablets combined with conventional antiplatelet drugs
control group:conventional antiplatelet drugs
Sponsors
The First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria of cerebral infarction in convalescence; 2. Patients without other nervous system diseases; 3. Patients aged 18-80 years, regardless of gender; 4. Patients with no recent acute infectious diseases or previous history of brain injury; 5. Patients and their families sign informed consent voluntarily; 6. Patients with clear consciousness, primary school education or above, can cooperate with the scale evaluation; 7. Patients with first onset, 2 weeks < course <= 3 months; 8. At the time of enrollment, 5 <= NIHSS score <= 20.
Exclusion criteria
Exclusion criteria: 1. Subjects allergic to pentoxifylline and other methylsulfonpurine drugs; 2. Patients with mental illness or dementia; 3. Patients with important organ dysfunction; 4. Patients with other conditions (acute myocardial infarction, active massive hemorrhage, retinal hemorrhage, severe arrhythmia, severe hypotension, etc.) that are not suitable for long-term use of pentoxifylline sustained-release tablets; 5. Patients whose expected survival time is less than 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIHSS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate of stroke; | — |
Countries
China
Contacts
Public ContactKezhong Zhang
The First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed